The phase 3 CheckMate 9DW trial, presented at ASCO24, brings promising results for nivolumab (NIVO) + ipilimumab (IPI) as a potential new standard of care in first-line treatment for unresectable hepatocellular carcinoma (uHCC).
Key Findings:
Significant overall survival (OS) benefit: 23.7 months with NIVO+IPI vs 20.6 months with lenvatinib (LEN)/sorafenib (SOR) (HR 0.79, p=0.018)
Higher objective response rate (ORR): 36% vs 13% (p<0.0001)
Complete response: 7% vs 2%
Median duration of response (DOR): 30.4 months vs 12.9 months
Manageable safety profile, supporting its potential as a first-line treatment option
These findings mark an important step in improving long-term outcomes for patients with uHCC.
Acknowledging the experts behind this study for their dedication to advancing liver cancer treatment.
Read more: https://lnkd.in/d5DzNq6Z
